GSK secures expanded EC approval for Jemperli plus chemotherapy
The expanded approval is based on results from the Phase 3 RUBY Part 1 trial, which showed a clinically meaningful and statistically significant overall survival (OS) benefit in primary advanced...
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry